Sun Pharma launches cancer drug in US market

| | New Delhi
  • 0

Sun Pharma launches cancer drug in US market

Monday, 08 April 2019 | PTI | New Delhi

Sun Pharma launches cancer drug in US market

Drug major Sun Pharmaceutical Industries Monday announced launch of  INFUGEM injection, used for treatment of cancer, in the US market.

In July 2018, Sun Pharma had received approval from the US health regulator for INFUGEM injection.

"INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the US," Sun Pharma said in a regulatory filing.

"INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the US Food and Drug Administration (USFDA) in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer," the company added.

Sun Pharma said INFUGEM uses its proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in ready-to-infuse final dosage bags.

Shares of Sun Pharmaceutical Industries were trading at Rs 462.30 apiece, 0.09 per cent lower, from the previous close on the BSE.

 

Sunday Edition

The Tuning Fork | The indebted life

10 November 2024 | C V Srikanth | Agenda

A comic journey | From Nostalgia to a Bright New Future

10 November 2024 | Supriya Ghaytadak | Agenda

A Taste of China, Painted in Red

10 November 2024 | SAKSHI PRIYA | Agenda

Cranberry Coffee and Beyond

10 November 2024 | Gyaneshwar Dayal | Agenda

The Timeless Allure of Delhi Bazaars

10 November 2024 | Kanishka srivastava | Agenda

A Soulful Sojourn in Puri and Konark

10 November 2024 | VISHESH SHUKLA | Agenda